
Gene Therapy
Vectors

Inspired By Nature – Motivated by Health
What we offer
Unique approach
AAV Peptide display, combined with unique DNA barcoding and next generation sequencing allows for easy screening of AAV libraries containing millions of rationally designed, targeted AAV variants in a single screen.
Fast & Flexible
Choose your target, tissue type, cell population or application. rAAVen designs a targeted, rationally designed AAV peptide display library which can be combined by a generated library of promotor & enhancer elements for increased cell and tissue specific expression.
Translational at scale
rAAVen offers screening of the AAV peptide library in animal models ranging from rodents to non-human primates, ensuring that the delivered product translates within mammalian species and are prime candidates for clinical trials.
Advancing Gene Therapy Through Collaboration
At rAAVen Therapeutics, we are proud to collaborate with industry leaders and innovators to advance the frontiers of gene therapy. Our partners are integral to our mission of developing cutting-edge solutions and driving impactful change in the field of adeno-associated virus (AAV) technologies.
Partner with us
We love to connect with innovators who share our dedication to develop revolutionary gene therapies.
rAAVen News
Lena Mårtensson Joins rAAVen Board of Directors
Lena Mårtensson has been assigned to the rAAVen Therapeutics Board of Directors. Lena has an extensive background within Life Science, with multiple project and business
rAAVen to Present at Viral Vector Summit in Amsterdam
rAAVen Therapeutics will participate in the Viral Vector Formulation Process & Development Summit in Amsterdam 11-13 June. Our CSO, Patrick Aldrin-Kirk, will present the rAAVen
rAAVen and PCI Biotech Launch Photochemical Lysis Project
rAAVen Therapeutics is pleased to announce a new joint Photochemical Lysis project with PCI Biotech. In the project, rAAVen will develop and produce AAV, as